List of Excipients in Branded Drug BICALUTAMIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Golden State Medical Supply Inc	BICALUTAMIDE	bicalutamide	51407-010	HYPROMELLOSE
Golden State Medical Supply Inc	BICALUTAMIDE	bicalutamide	51407-010	LACTOSE MONOHYDRATE
Golden State Medical Supply Inc	BICALUTAMIDE	bicalutamide	51407-010	MAGNESIUM STEARATE
Golden State Medical Supply Inc	BICALUTAMIDE	bicalutamide	51407-010	POLYETHYLENE GLYCOL 300
Golden State Medical Supply Inc	BICALUTAMIDE	bicalutamide	51407-010	POVIDONE K30
Golden State Medical Supply Inc	BICALUTAMIDE	bicalutamide	51407-010	SODIUM STARCH GLYCOLATE TYPE A POTATO
Golden State Medical Supply Inc	BICALUTAMIDE	bicalutamide	51407-010	TITANIUM DIOXIDE

Generic Drugs Containing BICALUTAMIDE

Company	Ingredient	NDC	Excipient
Major Pharmaceuticals	bicalutamide	0904-6019	HYPROMELLOSE 2910
Major Pharmaceuticals	bicalutamide	0904-6019	LACTOSE MONOHYDRATE
Major Pharmaceuticals	bicalutamide	0904-6019	MAGNESIUM STEARATE
Major Pharmaceuticals	bicalutamide	0904-6019	POLYETHYLENE GLYCOL 400
Major Pharmaceuticals	bicalutamide	0904-6019	POVIDONE K30
Major Pharmaceuticals	bicalutamide	0904-6019	SODIUM STARCH GLYCOLATE TYPE A POTATO
Major Pharmaceuticals	bicalutamide	0904-6019	TITANIUM DIOXIDE

What are the Most Frequently-Used Excipients in BICALUTAMIDE?

# Of NDCs	Excipient
2	CELLULOSE, MICROCRYSTALLINE
1	COLLOIDAL SILICON DIOXIDE
2	CROSCARMELLOSE SODIUM
2	CROSPOVIDONE
5	HYPROMELLOSE
9	HYPROMELLOSE 2910
4	HYPROMELLOSES

Excipient Strategy and Commercial Opportunities for Bicalutamide

Last updated: February 26, 2026

Bicalutamide is a non-steroidal anti-androgen used primarily in prostate cancer therapy. Its formulation involves specific excipient choices that influence stability, bioavailability, and shelf life. The evolving landscape of excipient strategies offers multiple commercial opportunities for pharmaceutical developers.

What Are Key Excipients in Bicalutamide Formulations?

Bicalutamide is commonly formulated as oral tablets. The excipients used typically include:

• Diluent (filler): Lactose monohydrate, microcrystalline cellulose
• Disintegrant: Crospovidone, croscarmellose sodium
• Binder: Povidone (PVPK), hydroxypropyl methylcellulose (HPMC)
• Lubricant: Magnesium stearate
• Coating agents: Opadry or film-forming polymers

These excipients improve manufacturability, stability, and patient compliance. The choice depends on solubility, stability profile, and manufacturing process constraints.

How Does Excipient Choice Impact Bicalutamide Stability and Bioavailability?

Bicalutamide has poor aqueous solubility, influencing bioavailability. Excipient strategies aim to improve this via:

• Use of solubility-enhancing excipients: Cyclodextrins, surfactants like sodium lauryl sulfate
• Formulation modifications: Amorphous forms, nanocrystals, polymorph control
• Stability considerations: Selecting excipients that inhibit degradation pathways, such as oxidation or hydrolysis

Incorporating these excipients can increase bioavailability from approximately 1% to higher levels, potentially improving therapeutic efficacy.

What Are Current Trends in Excipient Development for Bicalutamide?

Emerging trends align with broader pharmaceutical innovation:

• Use of superdisintegrants: To promote rapid disintegration and dissolution
• Lipid-based excipients: To facilitate absorption via lymphatic routes
• Polymer modifications: To sustain release profiles and reduce dosing frequency
• Green excipients: To meet regulatory preferences for environmentally friendly materials

These strategies address patient compliance, therapeutic effectiveness, and regulatory compliance.

What Are Commercial Opportunities in Excipient Development?

Opportunities include:

• Modified-release formulations: Patents on specific excipient combinations that extend drug release or improve absorption
• Bioavailability enhancement: Creating excipients that significantly improve solubility and absorption, potentially expanding indications
• Generic and biosimilar markets: Using novel excipients to meet regulatory standards and differentiate products
• Partnerships with excipient suppliers: Developing proprietary excipients tailored for Bicalutamide formulations
• Regulatory pathways: Leveraging GRAS (Generally Recognized As Safe) approved excipients for expedited approval processes

The global prostate cancer treatment market is projected to reach $12.5 billion by 2027, presenting a growth window for improved formulations [1].

Regulatory and Manufacturing Considerations

• FDA and EMA guidelines emphasize safety and compatibility of excipients
• Excipient characterization and stability testing are required for approval
• APIs and excipients must meet Good Manufacturing Practice (GMP) standards
• Environmental impact influences selection, especially for sustainable and green excipients

Summary of Potential Market Strategies and Competitive Edge

Strategy	Benefit	Key Considerations
Develop sustained-release formulations	Longer dosing intervals, improved adherence	Patents on excipient combinations, patent expiration of current formulations
Optimize bioavailability	Lower dose, enhanced efficacy	Use of absorption enhancers, nanoparticle technology
Incorporate green excipients	Regulatory advantage, consumer appeal	Compatibility with API, stability profile
Partner with excipient suppliers	Proprietary formulations	Cost, supply chain security

Key Takeaways

• Excipients in bicalutamide formulations impact solubility, stability, and bioavailability.
• Emerging trends include lipid-based, polymeric, and green excipients.
• Commercial opportunities exist in modified-release, bioavailability enhancement, and green formulations.
• Regulatory frameworks necessitate thorough excipient characterization and safety validation.
• Strategic partnerships and patent protections provide competitive advantages.

FAQs

Q1: How does excipient choice affect bicalutamide's bioavailability?
It influences solubility and dissolution rate, directly impacting absorption and therapeutic effect.

Q2: Are there approved excipients specifically enhancing bicalutamide absorption?
No excipients are approved solely for enhancing bicalutamide absorption; solubility enhancers like cyclodextrins are used in formulations.

Q3: What are common challenges in formulating bicalutamide?
Poor water solubility, stability issues, and ensuring bioavailability consistency.

Q4: How can green excipients benefit commercial development?
They meet regulatory preferences, attract environmentally conscious consumers, and may streamline approval processes.

Q5: What partnerships could accelerate excipient innovation for bicalutamide?
Collaborations with excipient manufacturers specializing in bioavailability enhancers or sustainable materials.

---

References

[1] Research and Markets. (2022). Global Prostate Cancer Market Analysis. Retrieved from https://www.researchandmarkets.com